Artios Banks $153m On The Back Of Novartis And Merck KGaA Deals
UK Biotech Completes Impressive Series C
Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.
You may also be interested in...
VC Playbook: Pfizer Ventures senior managing partner Barbara Dalton shares insights into how the corporate venture group balances a dual mandate, the trade-offs needed and what success looks like for a CVC.
A report from Silicon Valley Bank breaking down 2021 investment trends reveals half-year figures already close to matching those for the whole of 2020 – itself a record-breaking year. In Vivo spoke with SVB’s EMEA head of life sciences and health care for a deeper dive into underlying causes.
With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.